Comparative molecular analyses of pancreatic cancer (PC): KRAS wild type vs. KRAS mutant tumors and primary tumors vs. distant metastases


Mohamed E. Salem, John Marshall, Rebecca Feldman, Michael J. Pishvaian, Wafik S. El-Deiry, Jimmy J. Hwang, Emil Lou, Hongkun Wang, Zoran Gatalica, Sandeep K. Reddy, Anthony Frank Shields, Philip Agop Philip


Targeted therapies have a minimal role in PC partly because of the molecular characterization is not well understood. Little is known about the molecular characteristics of subset of PC that doesn’t carry KRAS mutations. Better knowledge would enhance our ability to develop targeted therapies.

Download Publication